vs
ExlService Holdings, Inc.（EXLS）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
ExlService Holdings, Inc.的季度营收约是Bio-Techne的1.8倍（$542.6M vs $295.9M），Bio-Techne净利率更高（12.8% vs 11.1%，领先1.7%），ExlService Holdings, Inc.同比增速更快（12.7% vs -6.4%），过去两年ExlService Holdings, Inc.的营收复合增速更高（11.5% vs 4.2%）
ExlService Holdings Inc.是全球知名的分析与数字解决方案服务商，服务覆盖保险、医疗健康、银行金融服务、媒体、零售等多个行业，总部位于纽约，在美国、欧洲、亚洲、拉美、澳大利亚、南非等地拥有超过5.4万名专业从业人员。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
EXLS vs TECH — 直观对比
营收规模更大
EXLS
是对方的1.8倍
$295.9M
营收增速更快
EXLS
高出19.1%
-6.4%
净利率更高
TECH
高出1.7%
11.1%
两年增速更快
EXLS
近两年复合增速
4.2%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $542.6M | $295.9M |
| 净利润 | $60.2M | $38.0M |
| 毛利率 | 38.6% | 64.6% |
| 营业利润率 | 14.4% | 18.4% |
| 净利率 | 11.1% | 12.8% |
| 营收同比 | 12.7% | -6.4% |
| 净利润同比 | 18.9% | 68.3% |
| 每股收益（稀释后） | $0.38 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXLSTECH
| Q4 25 | $542.6M | $295.9M | ||
| Q3 25 | $529.6M | — | ||
| Q2 25 | $514.5M | $317.0M | ||
| Q1 25 | $501.0M | $316.2M | ||
| Q4 24 | $481.4M | $297.0M | ||
| Q3 24 | $472.1M | $289.5M | ||
| Q2 24 | $448.4M | $306.1M | ||
| Q1 24 | $436.5M | $303.4M |
净利润EXLSTECH
| Q4 25 | $60.2M | $38.0M | ||
| Q3 25 | $58.2M | — | ||
| Q2 25 | $66.1M | $-17.7M | ||
| Q1 25 | $66.6M | $22.6M | ||
| Q4 24 | $50.7M | $34.9M | ||
| Q3 24 | $53.0M | $33.6M | ||
| Q2 24 | $45.8M | $40.6M | ||
| Q1 24 | $48.8M | $49.1M |
毛利率EXLSTECH
| Q4 25 | 38.6% | 64.6% | ||
| Q3 25 | 38.5% | — | ||
| Q2 25 | 37.7% | 62.7% | ||
| Q1 25 | 38.6% | 67.9% | ||
| Q4 24 | 38.1% | 65.3% | ||
| Q3 24 | 37.8% | 63.2% | ||
| Q2 24 | 37.1% | 66.4% | ||
| Q1 24 | 37.4% | 67.4% |
营业利润率EXLSTECH
| Q4 25 | 14.4% | 18.4% | ||
| Q3 25 | 14.4% | — | ||
| Q2 25 | 15.8% | -7.5% | ||
| Q1 25 | 15.7% | 12.2% | ||
| Q4 24 | 14.8% | 16.0% | ||
| Q3 24 | 14.7% | 13.8% | ||
| Q2 24 | 13.7% | 15.0% | ||
| Q1 24 | 14.1% | 22.1% |
净利率EXLSTECH
| Q4 25 | 11.1% | 12.8% | ||
| Q3 25 | 11.0% | — | ||
| Q2 25 | 12.8% | -5.6% | ||
| Q1 25 | 13.3% | 7.1% | ||
| Q4 24 | 10.5% | 11.7% | ||
| Q3 24 | 11.2% | 11.6% | ||
| Q2 24 | 10.2% | 13.3% | ||
| Q1 24 | 11.2% | 16.2% |
每股收益（稀释后）EXLSTECH
| Q4 25 | $0.38 | $0.24 | ||
| Q3 25 | $0.36 | — | ||
| Q2 25 | $0.40 | $-0.11 | ||
| Q1 25 | $0.40 | $0.14 | ||
| Q4 24 | $0.31 | $0.22 | ||
| Q3 24 | $0.33 | $0.21 | ||
| Q2 24 | $0.28 | $0.26 | ||
| Q1 24 | $0.29 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $328.4M | $172.9M |
| 总债务越低越好 | $298.6M | $260.0M |
| 股东权益账面价值 | $912.7M | $2.0B |
| 总资产 | $1.7B | $2.5B |
| 负债/权益比越低杠杆越低 | 0.33× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资EXLSTECH
| Q4 25 | $328.4M | $172.9M | ||
| Q3 25 | $390.1M | — | ||
| Q2 25 | $353.3M | $162.2M | ||
| Q1 25 | $331.4M | $140.7M | ||
| Q4 24 | $340.6M | $177.5M | ||
| Q3 24 | $325.8M | $187.5M | ||
| Q2 24 | $276.1M | $152.9M | ||
| Q1 24 | $246.2M | $145.3M |
总债务EXLSTECH
| Q4 25 | $298.6M | $260.0M | ||
| Q3 25 | $354.8M | — | ||
| Q2 25 | $260.0M | $346.0M | ||
| Q1 25 | $307.3M | $330.0M | ||
| Q4 24 | $288.5M | $300.0M | ||
| Q3 24 | $344.7M | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
股东权益EXLSTECH
| Q4 25 | $912.7M | $2.0B | ||
| Q3 25 | $952.4M | — | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $1.0B | $2.0B | ||
| Q4 24 | $929.9M | $2.1B | ||
| Q3 24 | $907.6M | $2.1B | ||
| Q2 24 | $852.6M | $2.1B | ||
| Q1 24 | $803.3M | $2.0B |
总资产EXLSTECH
| Q4 25 | $1.7B | $2.5B | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | $2.6B | ||
| Q1 25 | $1.7B | $2.6B | ||
| Q4 24 | $1.6B | $2.7B | ||
| Q3 24 | $1.6B | $2.7B | ||
| Q2 24 | $1.5B | $2.7B | ||
| Q1 24 | $1.4B | $2.7B |
负债/权益比EXLSTECH
| Q4 25 | 0.33× | 0.13× | ||
| Q3 25 | 0.37× | — | ||
| Q2 25 | 0.25× | 0.18× | ||
| Q1 25 | 0.30× | 0.16× | ||
| Q4 24 | 0.31× | 0.14× | ||
| Q3 24 | 0.38× | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $117.4M | — |
| 自由现金流经营现金流 - 资本支出 | $106.5M | — |
| 自由现金流率自由现金流/营收 | 19.6% | — |
| 资本支出强度资本支出/营收 | 2.0% | — |
| 现金转化率经营现金流/净利润 | 1.95× | — |
| 过去12个月自由现金流最近4个季度 | $298.1M | — |
8季度趋势，按日历期对齐
经营现金流EXLSTECH
| Q4 25 | $117.4M | — | ||
| Q3 25 | $120.7M | — | ||
| Q2 25 | $109.4M | $98.2M | ||
| Q1 25 | $3.2M | $41.1M | ||
| Q4 24 | $105.3M | $84.3M | ||
| Q3 24 | $110.1M | $63.9M | ||
| Q2 24 | $74.9M | $75.5M | ||
| Q1 24 | $-21.9M | $81.0M |
自由现金流EXLSTECH
| Q4 25 | $106.5M | — | ||
| Q3 25 | $106.4M | — | ||
| Q2 25 | $95.0M | $93.3M | ||
| Q1 25 | $-9.7M | $31.0M | ||
| Q4 24 | $95.3M | $77.5M | ||
| Q3 24 | $97.3M | $54.7M | ||
| Q2 24 | $62.8M | $57.5M | ||
| Q1 24 | $-33.1M | $64.5M |
自由现金流率EXLSTECH
| Q4 25 | 19.6% | — | ||
| Q3 25 | 20.1% | — | ||
| Q2 25 | 18.5% | 29.4% | ||
| Q1 25 | -1.9% | 9.8% | ||
| Q4 24 | 19.8% | 26.1% | ||
| Q3 24 | 20.6% | 18.9% | ||
| Q2 24 | 14.0% | 18.8% | ||
| Q1 24 | -7.6% | 21.3% |
资本支出强度EXLSTECH
| Q4 25 | 2.0% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 2.8% | 1.5% | ||
| Q1 25 | 2.6% | 3.2% | ||
| Q4 24 | 2.1% | 2.3% | ||
| Q3 24 | 2.7% | 3.2% | ||
| Q2 24 | 2.7% | 5.9% | ||
| Q1 24 | 2.6% | 5.4% |
现金转化率EXLSTECH
| Q4 25 | 1.95× | — | ||
| Q3 25 | 2.08× | — | ||
| Q2 25 | 1.66× | — | ||
| Q1 25 | 0.05× | 1.82× | ||
| Q4 24 | 2.08× | 2.42× | ||
| Q3 24 | 2.08× | 1.90× | ||
| Q2 24 | 1.63× | 1.86× | ||
| Q1 24 | -0.45× | 1.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXLS
| Insurance | $185.8M | 34% |
| Healthcare And Life Sciences | $142.2M | 26% |
| Banking Capital Markets And Diversified Industries | $122.6M | 23% |
| International Growth Markets | $92.0M | 17% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
